Oxford slowly gathered candidates, FDA wants 'something' light, nimble and quick to support FDA RWD and RWE on backs. Whelan showed his mettle in moving rapidly here to get that with a smaller back trial. The Oxford trial data can be used in the UK for the universal healthcare coverage addition under NHS . . . . .